LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Articles
Bitterroot Bio Inc.
Headquarters:
Palo Alto, CA, United States of America
Website:
https://www.bitterrootbio.com/...
Year Founded:
2021
Status:
Private
See
Emerging Company Profile
.
BioCentury
|
Sep 26, 2024
Discovery & Translation
Science Spotlight: Targeted protein relocalization, rejuvenating aged eggs, and more
BioCentury’s roundup of translational innovations
Read More
BioCentury
|
Jun 5, 2024
Management Tracks
Sanofi vet Frank Nestle joins Deerfield as partner, CEO of 3DC
Plus: Lilly CFO Anat Ashkenazi leaving for Alphabet, and updates from Y-mAbs, Danaher and more
Read More
BioCentury
|
Feb 3, 2024
Finance
Series A companies: the class of 2023
An analysis of the technologies behind last year’s biotech series A raisers finds clusters in mitophagy induction, epigenome editing and delivery vectors
Read More
BioCentury
|
Jun 7, 2023
Emerging Company Profile
Bitterroot: applying CD47 biology to cardiovascular disease
With IP from Stanford and Gilead, plus $145M from VCs, the cardio-immunology biotech is also aiming to build efficiencies into expensive CV trials
Read More
Items per page:
10
1 - 4 of 4
Help Center
Username
Request a Demo
Request Training
Ask a Question
Elevio by Dixa
Help